Establishment and characterization of 4 new human pancreatic cancer cell lines: Evidences of different tumor phenotypes

Pancreas

Volumn 38, Issue 2, 2009, Pages 184-196

  Chifenti, Barbara ^a,b   Morelli, Mariangela ^a   Zavaglia, Michele ^a   Coviello, Domenico A ^c   Guerneri, Silvana ^c   Santucci, Annalisa ^d   Paffetti, Alessandro ^d   Masetti, Massimo ^e   Locci, Maria Teresa ^e   Bertacca, Gloria ^a   Capodanno, Alessandra ^a   Collecchi, Paola ^a   Campani, Daniela ^a   Mosca, Franco ^b   Bevilacqua, Generoso ^a   Cavazzana, Andrea O ^f  

^a Molecular Pathology Section   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

^e UNIVERSITY OF PISA   (Italy)

^f UO Anatomy Pathology ASL N1 Massa e Carrara   (Italy)

Author keywords

Cell lines; Cytogenetic; Ezrin; Molecular genetics; Pancreatic cancer

Indexed keywords

AMINE DEHYDROGENASE; CELL DNA; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 7; CYTOKERATIN 8; EZRIN; K RAS PROTEIN; PROTEIN P53; VIMENTIN; KERATIN; SMAD4 PROTEIN; SMAD4 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CELL FUNCTION; CELL MEMBRANE; CELL MIGRATION; CELL STRUCTURE; CELLULAR DISTRIBUTION; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYTOGENETICS; DNA FINGERPRINTING; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; KARYOTYPE; MALE; MOLECULAR GENETICS; PANCREAS ADENOCARCINOMA; PANCREATIC DUCTAL ADENOCARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TIME; ADENOCARCINOMA; CELL MOTION; CELL PROLIFERATION; CHEMISTRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; IMMUNOHISTOCHEMISTRY; KARYOTYPING; MIDDLE AGED; ONCOGENE RAS; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DNA FINGERPRINTING; FEMALE; GENES, P16; GENES, P53; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; KERATINS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PHENOTYPE; SMAD4 PROTEIN; VIMENTIN;

EID: 65349175891     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31818c746a     Document Type: Article

References (75)

1. Kloppel G, Luttges J. The pathology of ductal-type pancreatic carcinomas and pancreatic intraepithelial neoplasia: insights for clinicians. Curr Gastroenterol Rep. 2004;6:111-118.
2. Luttges J, Stigge C, Pacena M, et al. Rare ductal adenocarcinoma of the pancreas in patients younger than age 40 years. Cancer. 2004; 100:173-182.
3. Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet. 2004;363: 1049-1057.
4. de Braud F, Cascinu S, Gatta G. Cancer of pancreas. Crit Rev Oncol Hematol. 2004;50:147-155.
5. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002;2:897-909.
6. Hezel AF, Kimmelman AC, Stanger BZ, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006;20:1218-1249.
7. Akanuma D, Uzawa N, Yoshida MA, et al. Inactivation patterns of the p16 (INK4a) gene in oral squamous cell carcinoma cell lines. Oral Oncol. 1999;35:476-483.
8. Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet. 1994;8:27-32.
9. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer. 2001;1:46-54.
10. Apte MV, Park S, Phillips PA, et al. Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas. 2004;29:179-187.
11. Ruggeri BA, Huang L, Berger D, et al. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions. Cancer. 1997;79:700-716.
12. Lemoine NR, Jain S, Hughes CM, et al. Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology. 1992;102: 230-236.
13. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682-4689.
14. Smit Vincent THBM, Boot AJM, Smits AMM, et al. K-Ras codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res. 1988;16:7773-7782.
15. Iacobuzio-Donahue CA, Song J, Parmiagiani G, et al. Missense mutations of MADH4: characterization of the mutational hot spot and functional consequences in human tumors. Clin Cancer Res. 2004;10:1597-1604.
16. Gibas M, Gibas Z, Sandberg AA. Technical aspect of cytogenetic analysis of human solid tumors karyogram. Genes Chromosome Cancer. 1984;10:2527.
17. Pinkel D, Straume T, Gray JW. Cytogenetic analysis using quantitative high sensitivity fluorescence hybridization. Proc Natl Acad Sci U S A. 1986;83:2934-2938.
18. Holm M, Thomsen M, Hoyer M, et al. Optimization of a flow cytometric method for the simultaneous measurement of cell surface antigen, DNA content, and in vitro BrdUrd incorporation into normal and malignant hematopoietic cells. Cytometry. 1998;32:28-36.
19. Istfan NW, Chen ZY, Rex S. Fish oil slows S phase progression and may cause upstream shift of DHFR replication origin ori-beta in CHO cells. Am J Physiol Cell Physiol. 2002;283:C1009-C1024.
20. Monti P, Marchesi F, Reni M, et al. A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behaviour and its correlation with the structural and genetic profile. Virchows Arch. 2004;445:236-247.
21. Jemal A, Siegel R, Waed E, et al. Cancer statistic 2006. CA Cancer J Clin. 2006;56:106-130.
22. Garcea G, Neal CP, Pattenden CJ, et al. Molecular prognostic markers in pancreatic cancer: a systematic review. 2005;41:2213-2236.
23. Kleeff J, Michalski C, Friess H, et al. Pancreatic cancer: from bench to 5-year survival. Pancreas. 2006;33:111-118.
24. Iacobuzio-Donahue CA, Ryu B, Hruban RH, et al. Exploring the host desmoplastic response to pancreatic carcinoma: gene expression of stromal and neoplastic cells at the site of primary invasion. Am J Pathol. 2002;160:91-99.
25. Ricci F, Kern SE, Hruban RH, et al. Stromal responses to carcinomas of the pancreas: juxtatumoral gene expression conforms to the infiltrating pattern and not the biologic subtype. Cancer Biol Ther. 2005;4:302-307.
26. Dalu K, Nobukazu N, Miki S, et al. Establishment and characterization of human pancreatic adenocarcinoma cell line in tissue culture and in the nude mouse. Tissue Cell. 2007;39:217-223.
27. Moore PS, Sipos B, Orlandini S, et al. Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-Ras, p53, CDKN2A and DPC4/ Smad4. Virchows Arch. 2001;439:798-802.
28. Sipos B, Moser S, Kalthoff H, et al. A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch. 2003;442:444-452.
29. Rajasekaran SA, Gopal J, Espineda C, et al. HPAF-II, a cell culture model to study pancreatic epithelial cell structure and function. Pancreas. 2004;29:e77-e83.
30. Shah AN, Summy JM, Zhang J, et al. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol. 2007;14:3629-3637.
31. Hsu JT, Yeh CN, Chen YR, et al. Adenosquamous carcinoma of the pancreas. Digestion. 2005;72:104-108.
32. Murakami Y, Yokoyama T, Yokoyama Y, et al. Adenosquamous carcinoma of the pancreas: preoperative diagnosis and molecular alterations. J Gastroenterol. 2003;38:1171-1175.
33. Rahemtullah A, Misdraji J, Pitman MB. Adenosquamous carcinoma of the pancreas: cytologic features in 14 cases. Cancer. 2003;99:372-378.
34. Meitner PA, Kajiji SM, LaPosta-Frazier N, et al. "COLO 357," a human pancreatic adenosquamous carcinoma: growth in artificial capillary culture and in nude mice. Cancer Res. 1983;43:5978-5985.
35. Ikeda Y, Ezaki M, Hayashi I, et al. Establishment and characterization of human pancreatic cancer cell lines in tissue culture and in nude mice Jpn J Cancer Res. 1990;81:987-993.
36. Kato M, Shimada Y, Tanaka H, et al. Characterization of six cell lines established from human pancreatic adenocarcinomas. Cancer. 1999;85:832-840.
37. Maitra A, Kern SE, Hruban RH. Molecular pathogenesis of pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006;20: 211-226.
38. Furukawa T, Sunamura M, Horii A. Molecular mechanisms of pancreatic carcinogenesis. Cancer Sci. 2006;97:1-7.
39. Howe JR, Conlon KC. The molecular genetics of pancreatic cancer. Surg Oncol. 1997;6:1-18.
40. INK4a in pancreatic ductal carcinoma. BMC Gastroenterol. 2005;28:5-22.
41. Moore PS, Orlandini S, Zamboni G, et al. Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Br J Cancer. 2001;84:253-262.
42. Moll R, Franke WW, Schiller DL, et al. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982;31:11-24.
43. Ramaekers F, Puts J, Moesker O, et al. Demonstration of keratin in human adenocarcinomas. Am J Pathol. 1983;111:213-223.
44. Real FX, Vilá MR, Skoudy A, et al. Intermediate filaments as differentiation markers of exocrine pancreas. II. Expression of cytokeratins of complex and stratified epithelia in normal pancreas and in pancreas cancer. Int J Cancer. 1993;54:720-727.
45. Bouwens L. Cytokeratins and cell differentiation in the pancreas. J Pathol. 1998;184:234-239.
46. Lee MJ, Lee HS, Kim WH, et al. Expression of mucins and cytokeratins in primary carcinomas of the digestive system. Mod Pathol. 2003;16:403-410.
47. Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, et al. Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res. 2005;11: 8006-8014.
48. Schüssler MH, Skoudy A, Ramaekers F, et al. Intermediate filaments as differentiation markers of normal pancreas and pancreas cancer. Am J Pathol. 1992;140:559-568.
49. Kim KR, Choi HN, Lee HJ, et al. A peroxisome-proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma. Oncol Rep. 2007;18: 825-832.
50. Kubota K, Kakuta Y, Kawamira S, et al. Undiferentiated spindle-cell carcinoma of the gallbladder: an immonohistochemical study. J Hepatobil Pancreat Surg. 2006;13:468-471.
51. Hoorens A, Prenzel K, Lemoine NR, et al. Undifferentiated carcinoma of the pancreas: analysis of intermediated filament profile and Ki-ras mutations provides evidence of a ductal origin. J Pathol. 1998;185:53-60.
52. Chu YW, Seftor EA, Romer LH, et al. Experimental coexpression of vimentin and keratin intermediate filaments in human melanoma cells augments motility. Am J Pathol. 1996;148:63-69.
53. Utsunomiya T, Yao T, Masuda K, et al. Vimentin-positive adenocarcinomas of the stomach: co-expression of vimentin and cytokeratin. Histopathology. 1996;29:507-516.
54. Hendrix MJ, Seftor EA, Seftor RE, et al. Experimental coexpression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behaviour. Am J Pathol. 1997;150:483-495.
55. Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol. 2002;3: 586-599.
56. Lamb RF, Ozanne BW, Roy C, et al. Essential functions of ezrin in maintenance of cell shape lamellipodial extension in normal and transformed fibroblasts. Curr Biol. 1997;7:682-688.
57. Prag S, Parsons M, Keppler MD, et al. Activated ezrin promotes cell migration through recruitment of the GEF Dbl to lipid rafts and preferential downstream activation of Cdc42. Mol Biol Cell. 2007;18:2935-2948.
58. Komiya S, Shimizu M, Ikenouchi J, et al. Apical membrane and junctional complex formation during simple epithelial cell differentiation of F9 cells. Genes Cells. 2005;10:1065-1080.
59. Hunter KW. Ezrin, a key component in tumor metastasis. Trends Mol Med. 2004;10:201-204.
60. Akisawa N, Nishimori I, Iwamura T, et al. High levels of ezrin expressed by human pancreatic adenocarcinoma cell lines with high metastatic potential. Biochem Biophys Res Commun. 1999;258:395-400.
61. Bal N, Yildirim S, Nursal TZ, et al. Association of ezrin expression in intestinal and diffuse gastric carcinoma with clinicopathological parameters and tumor type. World J Gastroenterol. 2007;13: 3726-3729.
62. Elliott BE, Meens JA, SenGupta SK, et al. The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res. 2005;7:R365-R373.
63. Kowalski J, Morsberger LA, Blackford A, et al. Chromosomal abnormalities of adenocarcinoma of the pancreas: identifying early and late changes. Cancer Genet Cytogenet. 2007;178:26-35.
64. Bardi G, Johansson B, Pandis N, et al. Karyotypic abnormalities in tumours of the pancreas. Br J Cancer. 1993;67:1106-1112.
65. Seymour AB, Hruban RH, Redston M, et al. Allelotype of pancreatic adenocarcinoma. Cancer Res. 1994;54:2761-2764.
66. Sirivatanauksorn V, Sirivatanauksorn Y, Gorman PA, et al. Non-random chromosomal rearrangements in pancreatic cancer cell lines identified by spectral karyotyping. Int J Cancer. 2001;91: 350-358.
67. Johansson B, Bardi G, Heim S, et al. Nonrandom chromosomal rearrangements in pancreatic carcinomas. Cancer. 1992;69: 1674-1681.
68. Karhu R, Mahlamaki E, Kallioniemi A. Pancreatic adenocarcinoma - genetic portrait from chromosomes to microarrays. Genes Chromosomes Cancer. 2006;45:721-730.
69. Aguirre AJ, Brennan C, Bailey G, et al. High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci U S A. 2004;101:9067-9072.
70. Heidenblad M, Schoenmakers EF, Jonson T, et al. Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines. Cancer Res. 2004;64:3052-3059.
71. Nowak NJ, Gaile D, Conroy JM, et al. Genome-wide aberrations in pancreatic adenocarcinoma. Cancer Genet Cytogenet. 2005;161: 36-50.
72. Mastersa JR, Thomson JA, Daly-Burnsa B, et al. Short tandem repeat profiling provides an international reference standard for human cell lines. PNAS. 2001;98:8012-8017.
73. Masters J. False cell lines. Carcinogenesis. 2002;23:371.
74. Masters J. False cell lines. Int J Cancer. 2002;99:154.
75. Wallrapp C, Hahnel S, Boeck W, et al. Loss of the Y chromosome is a frequent chromosomal imbalance in pancreatic cancer and allow differentiation to chronic pancreatitis. 2001;91: 340-344.